Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

Claim 1. (Currently amended) Compounds A compound of formula I

$$N - (CH_2)_n$$

wherein

n is an integer from 4 2 to 4

R₁ is a hydrogen atom, hydroxyl group or lower C₁₋₆alkoxy group

R₂ is a hydrogen atom or a straight or branched lower C₁₋₆alkyl group

X is hydrogen, fluorine, chlorine, bromine, hydroxyl group, trifluoromethyl group, 3,4-di-Cl,2,4-di-Cl or lower C₁₋₆ alkoxy group

and <u>an</u> enantiomers, diastereoisomers or racemates thereof-<u>or the</u>, <u>and a</u> physiologically acceptable acid addition salts thereof.

Claim 2. (Currently amended) The compounds according to claim 1 in which n is an integer 2, R₁ is a hydroxyl group, R₂ a methyl, ethyl, n-propyl, isopropyl, n-butyl or isobutyl group and X is a hydrogen atom, or phenyl disubstituted with 2 chlorine atoms in the positions 3 and 4 or in the positions 2 and 4 3,4-dichlorophenyl or 2,4-dichlorophenyl.

Claim 3. (Currently amended) The compounds according to claim 1 in which R_1 is a hydroxyl group in the RS configuration.

Claim 4. (Previously presented) The compound according to claim 1 which is 1-(3-pyridyl-2-(N-(2-(3,4-dichlorophenyl)ethyl-N-propylamino)ethanol and a dihydrobromide salt thereof.

Claim 5. (Previously presented) The compound according to claim 1 which is 1-(3-pyridyl)-2-(N-(2-phenylethyl)-N-propylamino)ethanol and a dihydrobromide salt thereof.

Claim 6. (Previously presented) The compound according to claim 1 which is 1-(3-pyridyl)-2-(N-(2-(3,4-dichlorophenyl)ethyl-N-methylamino)ethanol and a dihydrobromide salt thereof.

Claim 7. (Currently amended) The compound according to claim 1 which is 1-(4-pyridyl)-2-(N-(2-(3,4-dichlorophenyl)ethyl-N-methylamino)ethanol and a dihydrobromide salt thereof.

Claim 8. (Currently amended) The compounds of formula I according to claim 1 and the physiologically acceptable acid addition salts thereof as the ligands of sigma receptors for inhibiting cholesterol biosynthesis in the treatment of hypercholesterolemia and hyperlipemia in humans.

Claim 9. (Previously presented) The pharmaceutical compositions comprising the compound of formula I according to claim 1 and the physiologically acceptable acid addition salts thereof.

Claim 10 (canceled).

Claim 11. (Currently amended) The process for preparation of the compounds of formula I according to claim 1 which process comprises

a) alkylating secondary amines of formula VI


wherein

b)

R₂ is as defined above in formula I and Z is a group

$$-$$


in which X is as defined above in formula I, with pyridyloxirane of formula VII



and, if desired, the obtained compounds of formula I are converted into the salt or alkylating primary amines of formula VIII

wherein R₂ is as defined above in formula I,

with pyridyloxirane of formula VII



to intermediate compounds of formula IX

wherein R_2 is as defined above in formula I,

and condensing with the derivatives of phenylacetic acid of formula X

wherein Z is as defined above,

to intermediate compounds of formula XI

and reducing them to the title compounds of formula I, and, if desired, converting them into the salt.